Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intelligent Bio Solutions (INBS) Accumulated Expenses (2021 - 2025)

Intelligent Bio Solutions has reported Accumulated Expenses over the past 4 years, most recently at $469381.0 for Q2 2024.

  • For Q2 2024, Accumulated Expenses rose 30.77% year-over-year to $469381.0; the TTM value through Jun 2024 reached $469381.0, up 30.77%, while the annual FY2024 figure was $469381.0, 30.77% up from the prior year.
  • Accumulated Expenses for Q2 2024 was $469381.0 at Intelligent Bio Solutions, down from $660010.0 in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $909187.0 in Q2 2022 and troughed at $102475.0 in Q2 2021.
  • A 4-year average of $361180.4 and a median of $358942.0 in 2023 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 787.23% in 2022 and later crashed 60.52% in 2023.
  • Year by year, Accumulated Expenses stood at $129212.0 in 2021, then skyrocketed by 139.5% to $309469.0 in 2022, then grew by 18.56% to $366893.0 in 2023, then increased by 27.93% to $469381.0 in 2024.
  • Business Quant data shows Accumulated Expenses for INBS at $469381.0 in Q2 2024, $660010.0 in Q1 2024, and $366893.0 in Q4 2023.